Metropolis Healthcare Ltd. records 26% YoY growth in non-covid revenue* for Q1FY23 to Rs. 262 Crs.

 Metropolis Healthcare Ltd., a leading diagnostic service provider wherein today they have announced its audited consolidated financial results for (Q1FY23). 

Also, their total B2C Revenue grew by 28% YoY in Q1FY23.

SHARING BELOW SOME OF THE KEY HIGHLIGHTS

• Non-Covid Home Visits revenue increased by 30% YoY Rs. 23 Crs.
• Specialized tests contributed 42% to the Non-Covid revenue
• EBITDA margin (Before CSR & ESOP) stood at 25.6

In INR Crs.	Q1FY23	Q1FY22
Revenue from Operations	279.9	326.8
EBIDTA (before CSR & ESOP)	71.7	105.6
EBIDTA margin (before CSR & ESOP)	25.6%	32.3%
Profit After Tax	33.6	63.0*
PAT Margin (%)	12.0%	19.3%

“I am extremely pleased to share that we have recorded 26% growth on year-on-year basis for non-covid business inspite of the challenging business environment. Covid and Covid allied revenue witnessed a sharp fall as expected in line with the drop in number of covid cases. Going ahead, we expect the non-covid revenue to revert back to the sustainable growth rates recorded in pre-covid days.

We at Metropolis will continue to build our scientific capabilities, expand our network of labs and patient collection centres, build a superior customer experience, and will also focus on wellness and chronic testing segment. We are excited about the differentiation we have been able to create over the years and believe our company has a long runway of growth.”- Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Ltd.